Table 2—

Changes per intervention group after 6 months

Placebo500 μg*1,000 μg*Change 500 μg vs. placeboChange 1,000 μg vs. placeboChange 1,000 μg vs. 500 μg
n171415
Total dose of insulin (units)−1.2 ± 7.31.8 ± 5.20.0 ± 3.13.0 (−2.1 to 8.1)1.2 (−3.7 to 6.2)−1.8 (−7.1 to 3.5)
A1C (%)−0.3 ± 0.8−0.5 ± 0.8−0.3 ± 0.8−0.2 (−1.0 to 0.6)0.0 (−0.8 to 0.8)0.2 (−0.6 to 1.0)
Systolic blood pressure (mmHg)−7 ± 19−7 ± 15−1 ± 210 (−17 to 17)6 (−10 to 22)6 (−11 to 23)
Diastolic blood pressure (mmHg)−6 ± 7−4 ± 110 ± 112 (−6 to 11)7 (−2 to 15)4 (−5 to 13)
BMI (kg/m2)0.0 ± 0.70.2 ± 1.10.2 ± 1.00.2 (−0.7 to 1.0)0.3 (−0.5 to 1.1)0.1 (−0.8 to 1.0)
Total cholesterol (mmol/l)0.2 ± 1.2−0.2 ± 0.80.1 ± 0.4−0.4 (−1.2 to 0.4)−0.2 (−0.9 to 0.6)0.2 (−0.6 to 1.0)
Total-to-HDL cholesterol ratio−0.3 ± 0.4−0.2 ± 0.7−0.3 ± 0.50.2 (−0.3 to 0.7)0.0 (−0.5 to 0.5)−0.2 (−0.7 to 0.3)
Triglycerides (mmol/l)1.0 ± 4.3−0.1 ± 0.9−0.2 ± 0.5−1,1 (−3.5 to 1.3)−1,2 (−3.5 to 1.2)0.0 (−2.5 to 2.4)
HDL (mmol/l)0.1 ± 0.1−0.1 ± 0.30.1 ± 0.1−0.2 (−0.3 to 0.0)0.0 (−0.1 to 0.2)0.2 (0.0–0.3)
LDL (mmol/l)0.3 ± 0.7−0.1 ± 0.60.0 ± 0.4−0.3 (−1.4 to 0.7)−0.3 (−1.3 to 0.7)0.1 (−1.0 to 1.1)
Chromium (nmol/l)016 ± 1650 ± 2816 (−4 to 36)49 (30–69)33 (14–52)
  • Data are means ± SD within the group and mean differences between groups (95% CI) (Bonferroni corrected).

  • * Five hundred μg chromium and 1,000 μg chromium as chromiumpicolinate.

  • P = 0.041.

  • The chromium concentration increased above the detection limit in no patients in the placebo group. The chromium concentration increased above this limit in all patients in both intervention groups.